Genetic variation in the TP63 gene is associated with lung cancer risk in the Han population

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 1863-1866

  Hu, Qun Ying ^a   Jin, Tian Bo ^a,b,c   Wang, Li ^a   Zhang, Le ^b   Geng, Tingting ^c   Liang, Guinian ^a   Kang, Long Li ^a,d  

^a XIZANG MINZU UNIVERSITY   (China)

^b NORTHWEST UNIVERSITY   (China)

^c National Engineering Research Center for Miniaturized Detection System   (China)

^d National Engineering Research Center for Miniaturized Detection Systems ^*  (China)

Author keywords

Case control studies; Lung cancer; Single nucleotide polymorphism; TP63

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CHINA; CHINESE; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TP63 GENE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84898906301     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1248-3     Document Type: Article

References (17)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Chen WQ, Zhang SW, Zou XN, Zhao P. Cancer incidence and mortality in China, 2006. Chin J Cancer Res. 2011;23:3-9.
3. Chen WQ, Zhang SW, Zou XN. Evaluation on the incidence, mortality and tendency of lung cancer in China. Thorac Cancer. 2010;1:35-40.
4. Shields PG. Molecular epidemiology of smoking and lung cancer. Oncogene. 2002;21:6870-6.
5. Wang Y, Broderick P, Matakidou A, Vijayakrishnan J, Eisen T, Houlston RS. Variation in TP63 is associated with lung adenocarcinoma in the UK population. Cancer Epidemiol Biomarkers Prev. 2011;20:1453-62.
6. Hu Z, Wu C, Shi Y, Guo H, Zhao X, Yin Z, et al. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet. 2011;43:792-6.
7. Rafnar T, Sulem P, Besenbacher S, Gudbjartsson DF, Zanon C, Gudmundsson J, et al. Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk. Cancer Res. 2011;71:1356-61.
8. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. 2009; UNIT 2.12. doi: 10.1002/0471142905.
9. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347-51.
10. 2 for comparison of 2 independent examples. Cesk Zdrav. 1964;12:613-9.
11. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928-9.
12. Bland JM, Altman DG. Statistics notes. The odds ratio. BMJ. 2000;320:1468.
13. Flores ER. The roles of p63 in cancer. Cell Cycle. 2007;6:300-4.
14. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat. 1999;14:1-8.
15. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ. 2011;18:1487-99.
16. Massion PP, Zou Y, Uner H, Kiatsimkul P, Wolf HJ, Baron AE, et al. Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer. PLoS ONE. 2009;4:e5611.
17. Miki D, Kubo M, Takahashi A, Yoon KA, Kim J, Lee GK, et al. Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet. 2010;42:893-6.